Increased strength formulation of Ventavis launched - MPR

Links shared publicly online about this topic.

1,778
total visits

Increased strength formulation of Ventavis launched - MPR

Actelion Pharmaceuticals has launched an increased strength formulation of Ventavis (iloprost inhalation solution), an inhaled prostacyclin analogue, for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New York Heart Association (NYHA) Class III or IV symptoms.

View full resource at empr.com

Tags: Heart, Heart Disease, High Blood Pressure, Pharma, Pulmonology, News

Most Recently Shared on September 2, 2009 at 2:22 pm By:

MPR

MPR News: Increased strength formulation of Ventavis launched: Actelion Pharmaceuticals has launched an.. http://bit.ly/15RRLU

3 years ago...

Retweet

Favorite

Actelion launches new 20 mcg/mL Ventavis formulation

news-medical.net — “Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.” View full resource at news-medical.net